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Abstract: Anionic antimicrobial peptides (AAMPs) with net charges ranging from -1 to -8 have been identified in frogs, 
toads, newts and salamanders across Africa, South America and China. Most of these peptides show antibacterial 
activity and a number of them are multifunctional, variously showing antifungal activity, anticancer action, neuropeptide 
function and the ability to potentiate conventional antibiotics. Antimicrobial mechanisms proposed for these AAMPs, 
include toroidal pore formation and the Shai-Huang-Matsazuki model of membrane interaction along with pH dependent 
amyloidogenesis and membranolysis via tilted peptide formation. The potential for therapeutic and biotechnical 
application of these AAMPs has been demonstrated, including the development of amyloid-based nanomaterials and 
antiviral agents. It is concluded that amphibian AAMPs represent an untapped potential source of biologically active 
agents and merit far greater research interest. 
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1. INTRODUCTION 
 Over the centuries, skin extracts from frogs and toads have been used as traditional medicine in many cultures ranging from 
that of ancient Egypt to China [1]. For example, Chan Su is derived from the dried skin and venom gland secretions of toads 
from the Bufo genus and is used in Chinese traditional medicines as a remedy for numerous conditions [2]. The earliest 
recorded use of this preparation appears to be in the Tang Dynasty (618 to 907 AD), and it is now known that the major active 
ingredients in Chan Su are bufadienolides, which are steroids or cardiac glycosides [3]. It is also now known that a wide variety 
of bioactive compounds are found in the skin secretions of amphibians [4], including peptides, ranging from those with 
myotropical and antioxidant properties to those with antimicrobial and anticancer activity (Table 1) [5-6]. Many of these 
peptides are pleiotropic. For example, some antimicrobial peptides (AMPs) exhibit antibacterial, antifungal, antiviral and 
anticancer action [7-8]. Amphibian skin is a particularly rich repository of AMPs [5-6] and was the source of one of the first of 
these peptides to be discovered, namely magainin from Xenopus laevis in the early 1980s [9]. Homologues of magainin have 
since been identified in other species of the Xenopodinae and studies on the phylogenic and evolutionary relationships between 
amphibian AMPs have estimated that the ancestral genes of these peptides may be up to around 200 million years old [10-11]. 
Indeed, it is now generally accepted that AMPs are ancient endogenous components of the innate immune system and exert 
their antimicrobial activity via membrane interactions that involve relatively non-specific mechanisms at multiple sites of 
action [12]. Microbes appear to have a limited capacity to defend themselves against this multi-faceted activity with the result 
that the resistance of these organisms to AMPs has a low incidence and is generally due to inherent rather than adaptive 
mechanisms [13-14]. It has been proposed that these observations may help explain the fact that these peptides have maintained 
their efficacy over evolutionary time and led to the generally held view that microbial resistance to AMPs is unlikely to 
approach that shown by these organisms to conventional antibiotics [15-16]. This gives AMPs a major medical advantage over 
other antimicrobials and makes them attractive propositions to combat the global problem of infectious diseases due to drug 
resistant microbial pathogens [17-18]. In this capacity, a number of these peptides have been trialled in clinical regimes [19-
20], including magainin in the form of pexiganan for the treatment of diabetic foot infections and ulcers [21]. 
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Table 1. Major bioactive peptides found in the secretions of amphibian skin. Table 1 was compiled from Xu and Lai [5]. 
  
 
 
 
 
 
 
 
 
 
The vast majority of AMPs so far reported [22], including those in clinical trials [19-21], are cationic (CAMPs), which is likely 
to be an evolutionary adaptation that allows these peptides to target and interact with anionic components of microbial 
membranes [23-24]. In general, these interactions are an early step in the antimicrobial mechanisms of these AMPs, and this 
type of interaction leads to the disruption of membranes or translocation of the peptides across membranes to utilise 
intracellular sites of action [12, 24-25]. However, a growing number of anionic AMPs (AAMPs) are also being reported [26-
30] and some of the most prolific producers of these peptides are amphibians (Tables 2 & 3). Currently, these amphibians have 
been identified across three continents and here, we review the AAMPs produced by these organisms in relation to their 
antimicrobial activity and other biological roles (Table 4). 
 
2. AMPHIBIAN AAMPS FROM AFRICA AND SOUTH AMERICA 
 More commonly known as the African clawed frog, X. laevis, is native to sub-Saharan Africa, and currently, this amphibian 
is the most prolific, known producer of AAMPs with three of the these peptides credited to its antimicrobial arsenal [31-33]. In 
1997, PYL (net charge -5) was isolated from X. laevis, making this the first major example of an AAMP to be reported. 
Characterisation of PYL showed it to be a sequence of homopolymeric aspartate residues with weak Zn2+ mediated activity 
against Gram-positive bacteria, such as Serratia marcescens, and Gram-negative bacteria, including Pasteurella haemolytica 
[31]. Interestingly, this work earned X. laevis a central position in the history of AMPs in that it was the first eukaryotic host 
shown to produce both AAMPs and CAMPs [10-11], although the amphibian is now, perhaps better known for its world-wide 
invasive presence, primarily due to its global use as a model organism [34]. More recently, XLAsp-P1 (net charge -5) was 
identified in the skin of X. laevis, which in contrast to PYL, showed antibacterial activity that did not appear to require the 
presence of Zn2+ ions. The peptide exhibited activity against Gram-negative bacteria, such as Aeruginosus bacillus, and Gram-
positive organisms, including Aerococcus viridians, which appeared to involve a membranolytic mode of action that resembled 
a toroidal pore type mechanism [33].  Most recently, a peptide, designated XLAsp-P2 (net charge -5), was also identified in the 
skin of X. laevis, which showed activity against the fungus, Candida albicans, Gram-negative bacteria, such as Escherichia 
coli, and in particular, Gram-positive bacteria, including Staphylococcus aureus and its chloramphenicol resistant strain, 
RN4200. Mechanisms underpinning the antibacterial activity of the peptide were investigated and appeared to primarily involve 
membrane disruption, which was accompanied by attack on the DNA of these organisms [32]. These observations are 
consistent with the use of the Shai-Huang-Matsazuki (SHM) model of membrane interaction, which is a variant of the carpet 
mechanism that accommodates multiple sites of action and has previously been reported for AAMPs [27]. Studies on XLAsp-
P2 also showed that the peptide acted against S. aureus RN4200 and some E. coli strains in an additive manner with 
conventional antibiotics, such as the aminoglycoside, kanamycin, and the β-lactam, ampicillin [32]. This would appear to be 
one of the first reports of amphibian AAMPs potentiating the activity of conventional antibiotics, although this ability has been 
demonstrated for CAMPs from these organisms. For example, magainins and β-lactams were found to show synergistic activity 
against oxacillin-resistant S. aureus [51].  Interestingly, both XLAsp-P2 and XLAsp-P1 showed high levels of homology to 
PYL, also possessing aspartate rich regions (Table 2), and the primary role of the latter peptide is as the activation peptide of 
the PYL hormone found in X. laevis, inviting the speculation that the former two AAMPs may have similar multiple 
functionality [31, 33].  
 
 
 
Myotropical peptides Wound-healing peptides 
 
Opioid peptides Immunomodulatory peptides 
Corticotropin- releasing 
peptides 
Neuronal nitric oxide synthase 
inhibitors 
Angiotensins Antibacterial peptides 
Protease inhibitor peptides Antifungal peptides 
Neuropeptides Antiviral peptides 
Antioxidant peptides Antiparasitic peptides 
Lectins Anticancer peptides 
Insulin releasing peptides Pheromone peptides 
Mast cells degradation / 
histamine-releasing peptides 
Granains 
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Table 2. AAMPs from amphibians. 
AAMPs Sequence Host 
amphibian 
Key 
references 
He-1 DDDKTEE
EDDKENE
TTKVVE 
Hyla eximia  [35] 
Thaulin-4 DDGEEAE
SEAANPE
ENTVGG 
Pleurodema 
thaul 
[36] 
Octacidin DSVASSA
AQELSGV
LASN 
Osteocephalus 
taurinus 
[37] 
Pleurain-
C1 
YPELQQD
LIARLL 
Rana 
pleuraden 
[38] 
Pleurain-
C2 
FPELQQD
LIARLL 
Rana 
pleuraden 
[38] 
Brevinin-
1-AJ3 
FLPLAVSL
AANFLPK
LFCKITKN
VETLEME
LEII 
Amolops 
jingdongensis 
[39] 
Jingdongi
n-2 
FLPIVENC
SLVCWEN
NQKC 
 
Amolops 
jingdongensis 
[39] 
PopuDef GASPALW
GCDSFLG
YCRIACFA
HEASVGQ
KDCAEGM
ICCLPNVF 
Polypedates 
puerensis, 
[40] 
Defensin-
TK 
SPAIWGC
DSFLGYC
RLACFAH
EASVGQK
ECAEGML
CCIPNVF 
Theloderma 
kwangsiensis 
[41] 
CFBD-1 FAVWGCA
DYRGYCR
AACFAFE
YSLGPKG
CTEGYVC
CVPNTF  
Cynops 
fudingensis 
[42] 
PYL  ADADDDD
DK 
Xenopus laevis [31] 
XLAsp-
P1 
DEDDD Xenopus laevis [33] 
XLAsp-
P2 
DEDLDE Xenopus laevis [32] 
PD-3-7 LLGDLLG
QTSKLVN
DLTDTVG
SIV 
Pachymedusa 
dacnicolor 
[43] 
Maximin 
H5 
ILGPVLGL
VSDTLDD
VLGIL-
NH2 
Bombina 
maxima 
[44] 
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Table 3. Peptide B / enkelytin from amphibians. Table 3 shows the sequences of peptide B / enkelytin, which are encrypted 
within proenkephalin (PENK) of a variety of amphibians. Also shown are the SwissProt accession codes for these sequences, 
which are available at the SwissProt database, (http://web.expasy.org/docs/swiss-prot). 
Host 
amphibian 
Sequence Key references 
and SwissProt 
accession code 
Amphiuma 
means 
(Salamander) 
FTDYSAPSDEDGESYS
KEIPEMEKRYGGFMRF 
 
[45] 
Q6YIR4 
Necturus 
maculosus 
(Salamander) 
FADYSAPSDEDGESYS
KEIPEMEKRYGGFMRI 
[45] 
Q6YIR3 
Taricha 
granulose 
(Newt) 
FADSSAPSEEEAESYSK
EIPEMEKRYGGFMRY 
[46] 
Q5PZ00 
Xenopus 
laevis 
(Frog) 
FTDSFLPSDEDGESYSK
ENPDMEKRYGGFMRF 
[47] 
P01212 
Xenopus 
tropicalis 
(Frog) 
FTDSFLPSEEDGESYSK
ENPDMEKRYGGFMRF 
[48] 
F6Y5F6 
Bombina 
orientalis 
(Toad) 
FADSLLPSDEDGESYS
KEVPEVEKRYGGFMRF 
[49] 
Q5Y4B6 
Spea 
multiplicatus 
(Toad) 
FSDSVLPSDEDGESYSK
EIPEMDKRYGGFMRF 
[50] 
Q9I817 
 
 
Table 4. AAMPs from amphibians and their biological activities. 
AAMPs Anti- 
bacterial 
Anti- 
fungal 
Anti-cancer Other activities Key references 
He-1 - NT NT NT [35] 
Thaulin-4 - NT NT NT [36] 
Octacidin + NT NT NT [37] 
Pleurain-C1 + + NT NT [38] 
Pleurain-C2 NT NT NT NT [38] 
Brevinin-1-AJ3 NT NT NT NT [39] 
Jingdongin-2 - - NT NT [39] 
PopuDef + NT NT NT [40] 
Defensin-TK + + NT NT [41] 
CFBD-1 + + NT NT [42] 
PYL + _ _ Propeptide [31] 
XLAsp-P1 + NT + Propeptide [33] 
XLAsp-P2 + + NT Propeptide [32] 
PD-3-7 _ NT NT Insecticidal [52-53] 
Maximin H5 + _ + Neuropeptide [44, 54-56] 
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A number of AAMPs have been reported from South America, including those with the highest levels of negative charge: 
for example, almost a decade ago, he-1 with a net charge of -8 was identified in the Mountain tree frog, Hyla eximia, which is 
endemic to Mexico [35]. Most recently,  thaulin-4, which also has a net charge -8, was isolated from the Chilean four-eyed 
frog, Pleurodema thaul, which is widely distributed in Argentina and Chile [36]. In contrast, the Manaus slender-legged tree 
frog, Osteocephalus taurinus, native to many parts of South America and was found to produce octacidin (net charge -2) in its 
skin secretions. The peptide was predicted to form α-helical secondary structure and exhibited potent activity against a variety 
of Gram-negative bacteria, including Escherichia coli and Pseudomonas aeruginosa [37]. However, the most studied 
amphibian producer of AAMPs from South America would appear to be the Mexican giant tree frog, Pachymedusa dacnicolor, 
which is native to Southern Mexico, a number of dermaseptins have been identified in the amphibian [57]. Studies on the skin 
of P. dacnicolor led to the description of the AAMP, dermaseptin PD-3-7 (net charge -3), which was classified as an ‘orphan’ 
dermaseptin, but was not investigated for antimicrobial activity [43]. The dermaseptins are a superfamily of AMPs that can be 
divided into seven subfamilies and ‘orphan’ dermaseptins form a group whose members do not resemble those of the remaining 
subfamilies [58]. More recent studies on PD-3-7 showed that the peptide had an inherent propensity to adopt an extended 
conformation in aqueous solution and self-assemble in a reversible pH-controlled fashion to form amyloid fibrils [52], which is 
now generally regarded as a unique protein quaternary structure [59]. It was demonstrated that PD-3-7 existed as amyloid-like 
β-sheet aggregates at low pH but increasing pH led the peptide to undergo morphological changes, which were mediated by 
deprotonation of the aspartic acid residues and C-terminal carboxyl groups possessed by the peptide. These morphological 
changes led to the formation of metastable amorphous aggregates at high pH, which had no effect against E. coli and 
Bacillus subtilis but induced damage on cells of the insect, Spodoptera frugiperda [52]. The mechanism underpinning the 
activity of PD-3-7 against S. frugiperda was not elucidated, but it is known that AAMPs with amyloid-mediated modes of 
membrane interaction show activity against eukaryotic cells [12, 60-61], including fungi [62-63] and neurones [64-65]. 
More recent studies on amphibian L/D-isomerases suggested that P. dacnicolor  produced PD-3-7 as epimers, which differ 
by the stereochemical modification, L–Leu2 → d-Leu2 [66]. It is well established that epimeric AMPs are produced by 
amphibians [5], such as the Polka-dot tree frog, Hypsiboas punctatus [67], which produces phenylseptins.  Previous studies 
have suggested that the production of epimeric AAMPs is a strategy used to enhance the antimicrobial efficacy of some frogs 
and toads [26]. Studies that are more recent showed that the stereochemical modification, L–Leu2 → d-Leu2, strongly 
influenced the pH-triggered, morphological changes involved in amyloid formation by the PD-3-7 [53]. These morphological 
changes showed many similarities to those observed in amyloid formation by epimeric peptides from platypus venom [68-69] 
and Aβ42 and Aβ40, which appear to act as AAMPs in innate defence of the brain [60, 62-63]. In particular, the response of 
PD-3-7 epimers to changes in pH led to differences in their super structural organisation, which were related to the differing 
conformational propensities of these peptides [53]. Similar differences in folding propensity under conditions that promote self-
aggregation have also been reported for bombinins H2 and H4, which are epimeric peptides from toads of the Bombina genus 
[70]. It has been proposed that these differences in folding ability may contribute to the higher levels of membrane perturbation 
and antimicrobial activity observed for bombinin H4, which contains the L–Leu2 → d-Leu2 substitution, as compared to 
bombinin H2 [71]. The biological activities of [d-Leu2] PD-3-7 was not determined, but it appeared that the N-terminal 
conformation of PD-3-7 epimers critically and differentially affected fibril twist and thus their resulting superstructures, which 
led to the speculation that d-Leu2 may act as a switch to control amyloid formation [53].  It is well established that dysregulated 
amyloid formation is detrimental to the host [72] and it has previously been suggested that amyloidogenesis by PD-3-7 may 
represent a storage facility for the peptide [52] similar to pituitary peptide hormones [73]. In this scenario, triggered by an 
increase in pH, the PD-3-7 storage facility would release a preformed defence molecule that contributed to the innate immune 
system of P. dacnicolor [52].  
 
3. AMPHIBIAN AAMPS FROM CHINA 
Currently, the largest number of reported AAMPs from amphibians are those identified in China, such as the Yunnan 
pond frog, Rana pleuraden, (Babina pleuraden), which is native to South Western China and adjacent regions of Myanmar, and 
produces pleurain-C1 (net charge -1) and pleurain-C2 (net charge -1). These peptides differ by only a single residue at position 
1 (Y→F) and pleurain-C1 was found to possess both antibacterial activity, killing E. coli, S. aureus and Bacillus subtilis, and 
antifungal activity with action against C. albicans [38]. Two AAMPs were identified in the skin of the Chinese torrent frog, 
Amolops jingdongensis, which is also native to South Western China.  These AAMPs were designated brevinin-1-AJ3 (net 
charge -1) and jingdongin-2 (net charge -1) [39]. The latter peptide along with the CAMP, jindongin-1, appeared to constitute a 
novel family of AMPs with no similarity to known amphibian peptides [5], but both peptides showed the potential to form a C-
terminal cyclic region stabilised by a disulphide bond, Cys18-(Xaa)4-Lys-Cys24 (Table 2) [39], which is known as the ‘Rana 
box’ and is characteristic of AMPs from Ranid frogs [5-6]. The ‘Rana box’ is often associated with the antimicrobial activity of 
AMPs [74], but jingdongin-2 exhibited no activity against the panel of bacteria and fungi tested, although this panel was small 
[39]. Many brevinins form a ‘Rana box’ [5] and in the case of brevinin-1-AJ3, a sequence homologous to this motif, Cys18-
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(Xaa)4-Lys-Asn24 (Table 2) was present in the peptide’s primary structure, suggesting that Cys24 has been mutated to Asn24 
resulting in a loss of ability to form a ‘Rana box’ [39]. Brevinin-1-AJ3 was not characterised by the latter study and its 
properties remain unknown but many atypical brevinins with potent antimicrobial activity are known where the ‘Rana box’ of 
these peptides has either been lost or mutated [5, 75-77]. Brevinin-1-AJ3 and jingdongin-2 were also notable for the fact that 
they each contained a free half-cysteine residue [39], which is rare amongst AAMPs, evidenced by the small number of these 
peptides listed in the APD3 database [22]. These AAMPs have been identified in several sources [78] but most appear to be 
from plants [22], such as Cn-AMP3, which is one of several AAMPs found in the Coconut, Cocos nucifera [28, 79]. In general, 
the role of free cysteine residues in the activity of AMPs is unclear although recent work has suggested that these residues may 
play a role in facilitating peptide dimerization rather than directly promoting the antimicrobial activity of AMPs [80]. However, 
it is also interesting to note that an increasing number of multifunctional peptides are being identified in the skin of amphibians, 
both serving as AAMPs / CAMPs and possessing antioxidant activity, which is promoted by the presence of free half-cysteine 
residues [38, 81-82]. Indeed, a number of anionic antioxidant peptides have been reported that have yet to be tested for 
antimicrobial activity, such as andersonin-AOP1 (net charge -1) from Anderson’s frog, Odorrana andersonii which is found in 
the Yunnan Province of China and regions of neighbouring countries [83].  The Puer tree frog, Polypedates puerensis 
(Rhacophorus puerensis), is primarily known in the Yunnan Province of China, and was recently shown to be the host of the 
first anionic defensin from amphibians, PopuDef (net charge -1). It was found that the expression of PopuDef was upregulated 
in immune related tissues of P. puerensis, such as the skin and gut, in response to bacterial challenge. The peptide showed 
moderate activity against organisms able to induce its expression, including Gram-negative bacteria, such as P. aeruginosa 
and Gram-positive bacteria, including B. subtilis [40]. Since the discovery of PopuDef, a second amphibian anionic defensin 
has been identified in skin secretions of the tree frog, Theloderma kwangsiensis (Theloderma kwangsiense), which is mostly 
found in Eastern Guangxi Province, China. Designated defensin-TK (net charge -1), the peptide showed broad range 
antimicrobial activity with efficacy against C. albicans, Gram-positive bacteria, such as S. aureus, and Gram-negative bacteria, 
including B. dysenteriae [41]. Our own analyses using the SIM - Alignment Tool for protein sequences 
(http://web.expasy.org/sim/) revealed that there is circa 90% sequence homology between defensin-TK and PopuDef.  Given 
that these peptides have been identified in frogs from the same taxonomic family [84], this would suggest that defensin-TK and 
PopuDef may have originated from a common gene. Moreover, these latter two AAMPs showed homology of around 50% with 
CFBD-1, which is a defensin from the fire-bellied newt, Cynops fudingensis, a new species recently identified in North Eastern 
Fujian Province, China [40-41]. This peptide was mildly anionic (net charge - 0.4) and showed moderate activity against Gram-
positive bacteria, such as S. aureus, and weaker activity against other bacteria and fungi [42].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The processing of human proenkephalin A. Figure 1 was revised from [85-86] and shows a model for the processing 
of human proenkephalin (PENK) in response to microbial challenge. According to this model, the action of 
prohormoneconvertase 2 or 3 (SPC2/3) on the C-terminal region of PENK yields a segment containing peptide B. This segment 
is then cleaved to peptide B, which is then further fragmented by angiotensin converting enzyme (ACE) and neutral 
endopeptidase (NEP) to either enkelytin or M-enk-RF (Methionine-enkephalin-arginine-phenylalanine). Enkelytin is also 
degraded by ACE and NEP to M-enk (Methionine-enkaphalin). M-enk and M-enk-RF are opioid peptides and induce 
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chemotaxis whilst peptide B and enkelytin engage in antibacterial activity [85-86]. This strategy contrasts with  that used by 
maximin H5 and homologous AAMPs in the brains of B. maxima and B. microdeladigitora where antimicrobial and 
neuropeptide capability appear to be localised within single molecules [87]. 
 
CFBD-1 would appear to be the first AAMP to be characterised in salamanders, although evidence has been 
previously presented, which infers the presence of other AAMPs in the brains of these organisms (Table 3) [26]. In human 
brains, it is believed that peptide B (net charge -6) and its truncated form, enkelytin (net charge -7), are enzymatically cleaved 
from the opioid hormone, proenkephalin (PENK), in response shown to microbial challenge [85-86]. PENK processing to 
produce these AAMPs also generates opioid peptides and it is believed that this strategy helps provide an immediate, 
coordinated innate immune response to the threat of infection (Fig. 1) [26, 86]. PENK is highly conserved across the eukaryotic 
kingdom, and homologues of peptide B / enkelytin are encrypted within the sequence of this opioid hormone in a number of 
amphibians, as revealed by a search of the SwissProt database (http://web.expasy.org/docs/swiss-prot). Examples include 
salamanders, newts, frogs and toads, which strongly suggests that these AAMPs are present in the brains of organisms across 
Amphibia (Table 3). Recently, the PENK related potential to produce peptide B / enkelytin was reported for the Western 
clawed frog, Xenopus tropicalis (Silurana tropicalis), which is found in the West African rainforest belt and is closely related 
to X. laevis (Table 3) [48]. As a matter of historical interest, the PENK related potential to produce peptide B / enkelytin was 
identified in the latter organism over five years before it was shown to be the host of PYL, the first of demonstrated amphibian 
AAMPs [47]. 
The Yunnan firebelly toad, Bombina maxima, is native to the mountainous regions of South Western China and 
adjacent Northern Vietnam, and the skin secretions of the frog have been found to include maximin H5 (net charge – 1) [44], 
which is probably the best characterised of amphibian AAMPs [29, 54, 87-90]. A number of characterisation studies have 
shown that maximin H5 is a predominantly α-helical peptide with multiple biological roles, which are described below, and 
include: antibacterial action [44, 54, 89], anticancer activity [29, 55] and neuropeptide functions [56]. 
 
3.1.  The neuropeptide function of maximin H5 
Phylogenetic studies have shown that maximin H5 and homologous AAMPs belong to a suite of AMPs that has arisen 
through rapid gene diversification, driven by positive selection.  These are present in the brains of B. maxima and the Hubei, 
firebelly toad, Bombina microdeladigitora, which is a subspecies of B. maxima and occupies similar geographical regions [56, 
91]. This suite of AMPs included nearly 80 peptides, indicating an extreme of diversity that had not previously been reported 
for a single species of frog and the reason for which was unclear. However, evidence was presented, which suggested that 
maximin H5 and homologous AAMPs have anti-nociceptive properties and may also serve as neuropeptides [56]. This 
observation clearly suggested that the diversity of AMPs produced by B. maxima and B. microdeladigitora might enhance the 
capacity of these organisms for survival by providing peptides able to perform multiple roles in their innate immune response, 
giving a clear example of the functional promiscuity of AMPs [10, 92]. As a matter of historical interest, some of the earliest 
anionic peptides to be isolated from amphibians were bombesins and tachykinins from Pseudophryne güntheri [93], which are 
families of molecules that serve as hormones and neurotransmitters [94-95]. These signalling molecules have been extensively 
studied in amphibians [96-97] and it is now generally accepted that they are able to exert antimicrobial activity whilst, 
conversely, AAMPs produced by these organisms can exhibit immunomodulatory function [5, 98]. It may be that this strategy 
is common, although many anionic neuropeptides identified within frogs and toads have yet to be tested for antimicrobial 
potential [5, 99].  
 
3.2.  The antibacterial action of maximin H5 
Several studies have shown that maximin H5 exhibits activity against S. aureus [44, 54].  Recent experimental work and 
molecular dynamic (MD) simulations to involve membranolytic mechanisms [54, 89]. This work showed that the membrane 
interactive form of the peptide was a hairpin-type α-helical conformation whose partitioning into the bilayer was stabilised by a 
variety of lipid–peptide and intra peptide bonds. The major driver of the membranolytic mechanisms used by maximin H5 
appeared to be the formation of a tilted α-helix in the peptide’s amidated N-terminal segment, H2N-I1–S10 (Table 2).  This 
tilted α-helical structure induced deep bilayer penetration by this segment at an angle of circa 45° (Fig. 2A). Tilted α-helices 
possess an asymmetric distribution of hydrophobicity along the α-helical long axis that induces membrane penetration at a 
shallow angle, and have been identified in a number of AMPs, and AAMPs, such as Aβ42 and Aβ40 [12, 100]. The net 
negative charge carried by maximin H5 resulted from an internal cluster of aspartate residues, which formed a short α-helical 
region that flanked the N-terminal tilted α-helical segment of the peptide. These aspartate residues were distal from the 
membrane surface and appeared to play no direct role in the lipid interactions of maximin H5, rather, serving a primarily 
structural role [89]. The amidated C-terminal segment, V16-L20-NH2, of maximin H5 (Table 2) was found to play a key role in 
its membranolytic activity by forming an intra-peptide hydrogen bonding network with the N-terminal region of the peptide 
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that stabilised its tilted α-helical structure (Fig. 2A). A number of recent studies have shown that the activity of some AAMPs 
against S. aureus are influenced by pH [101], such as that of hebraein (net charge -4), which is produced by Amblyomma 
hebraeum [102] and other ticks [103-104]. This was also found to be the case for maximin H5 when a very recent study showed 
that low pH enhanced the membranolytic action of the peptide against S. aureus, making maximin H5 the only major 
amphibian AAMP reported to possess pH dependent antibacterial activity [54]. Low pH appeared to have the general effect of 
enhancing the levels of amphiphilic α-helical structure possessed by maximin H5, thereby maximising its membranolytic 
ability and facilitating the killing of S. aureus via a ‘carpet’-type mechanism [54, 89], which is that most commonly used by α-
helical AMPs [12, 105]. According to this mechanism, increasing levels of maximin H5 ‘carpet’ membranes of S. aureus in a 
nonspecific manner, thereby inducing progressively greater numbers of lesions and ultimately, membranolysis [54, 89]. It is 
believed that a number of other amphibian AMPs eradicate bacteria via the ‘Carpet’ mechanism with a tilted α-helical structure 
incorporated into their lytic action [12, 100].  Examples include  aurein 2.3 from Green and Golden Bell frog, Litoria aurea 
[106]. Comparisons were made between the tilted α-helix of maximin H5 [54, 107] and that of the anionic influenza 
haemagglutinin peptide, HA2 [100, 108], which has a low pH optimum for the adoption of tilted α-helical structure and 
membranolytic action [109]. These comparisons revealed many compositional and structural similarities between the two 
molecular architectures and led to the suggestion that low pH enhanced the activity of maximin H5 against S. aureus primarily 
by maximising its level of N-terminal tilted α-helical structure [54]. In combination, these observations indicate that maximin 
H5 exerts antibacterial activity via a pH dependent antimicrobial mechanism that has not yet been reported for AAMPs or, 
indeed, AMPs in general [101].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. MD simulations of maximin H5 interacting with bacterial cell membranes.  Figure 2 was revised from [89, 110] and 
depicts snapshots of MD simulations of the interaction of maximin H5 with various bacterial membranes. Figure 2A shows the 
peptide inserted into S. aureus membranes utilising a hairpin-type α-helical conformation whose partitioning into the bilayer 
was stabilised by a variety of lipid–peptide and intra peptide bonds and involved the peptide’s amidated terminal segments, 
H2N-I1–S10 and V16-L20-NH2 [89]. Maximum H5 shows specificity for S. aureus and appears to kill the organism via pH-
dependent membranolytic mechanisms that involve the strongly α-helical N-terminal region of the peptide [54]. Figure 2A 
clearly shows this N-terminal segment inserting into the membranes at an angle of circa 45°, which is typical of tilted AMPs 
[100, 111-112]. These observations strongly support previous studies, which have suggested that the antibacterial activity of the 
peptide may involve the pH dependent, adoption of membranolytic-tilted structure [54, 107]. Figure 2B shows MD simulations 
of maximin H5 interacting with the surface of E. coli membranes, which include circa 80% phosphatidylethanolamine (PE), 
and it appears that the high affinity of the peptide for PE renders it immobilised on the surface of these membranes [88]. Figure 
2C shows an enlarged version of Figure 2B, which indicates that in the presence of PE, maximin H5 undergoes a 
conformational change that leads to random coil structure in its amidated N-terminal tilted segment, H2N-I1–S10, and the 
absence of intra peptide interactions between this segment and the amidated C-terminal segment, V16-L20-NH2, of the peptide. 
This conformational rearrangement promotes membrane binding by maximin H5 with the major contributions coming from 
hydrogen bonding between phosphate and ammonium groups within the PE head-group and residues in both terminal regions 
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of the peptide. In particular, the N-terminal region of maximin H5 shows high affinity for PE, which was proposed to involve 
the ability of this segment to mimic structural properties of the PE-binding pocket formed by a number of prokaryotic AMPs. In 
combination, these various interactions appear to anchor maximin H5 to the surface of E. coli membranes, thereby inhibiting 
the ability of the peptide to adopt the membrane interactive tilted α-helical structure necessary for its antimicrobial activity [88, 
110].  
 
 
3.3.  Bacterial resistance to the action of maximin H5 
S. aureus has evolved a wide repertoire of resistance mechanisms to counter the action of AMPs and other host defence 
molecules [113-114] including a number that are influenced by pH [101], as recently shown for the resistance of both S. aureus 
and methicillin-resistant S. aureus (MRSA) to analogues of magainin 2 from X. laevis [115]. This possibility was investigated 
for maximin H5, and it was found that S. aureus had developed protection from the action of the peptide. This protection was 
pH dependent and involved lys-PG in the membranes of the organism [54]. It is well established that levels of lys-PG in S. 
aureus membranes are elevated at low pH, which enhances the ability of the lipid to attenuate properties of these membranes 
and thereby enable the organism to resist AMPs [115]. Consistent with these observations, it was shown that the elevated levels 
of lys-PG present in S. aureus membranes at low pH reduced the net negative surface charge carried by these membranes and 
affected characteristics of their structural order, such as lipid packing and membrane fluidity, thereby inducing rigidification. 
These effects appeared to inhibit the ability of maximin H5 to target and penetrate membranes of S. aureus, which was 
surprising given that the peptide carries a net negative charge [44] and lys-PG mediated mechanisms of resistance appear to 
have evolved primarily to protect the organism from CAMPs [19, 114]. To explain this apparent contradiction, it was suggested 
that the membranolytic form of maximum H5 effectively acted as a CAMP via the amidated residues at its two termini, which 
are the only positively charged residues possessed by the peptide [54]. Consistent with this suggestion, MD simulations showed 
that these amidated residues were relatively more accessible to external molecules than the internally located, anionic residues 
possessed by the peptide (Fig. 2) [88, 90, 110]. These findings appeared to help explain how maximum H5 targeted membranes 
of S. aureus and also why the peptide was able to evade some adaptive mechanisms of resistance possessed by the organism to 
combat anionic AMPs [114, 116]. Further investigations into the antimicrobial action of maximin H5 showed that with the 
exception of S. aureus, the peptide had no activity against other Gram-positive bacteria, Gram-negative bacteria, fungi or 
enveloped viruses [44, 88, 90, 117]. A clear difference between these two groups of microbes was the presence of 
phosphatidylethanolamine (PE) in the membranes of organisms resistant to the action of maximin H5 and the absence of this 
lipid in the membranes of microbes susceptible to its activity [118-120]. Studies on E. coli showed that maximin H5 had no 
propensity to partition into membranes derived from this organism, or other PE-containing membranes.  Also the peptide was 
predicted by MD simulations to remain bound to the surface of these bilayers via a variety of peptide-lipid interactions and 
intra-peptide associations (Figs 2B and 2C). The major contributions to this peptide-membrane binding came from hydrogen 
bonding between phosphate and ammonium groups within the PE head-group and residues in both terminal regions of maximin 
H5 [88, 110]. Essentially, in relation to the membranolytic form of the peptide (Fig. 2A) [89-90], maximin H5 appeared to 
undergo a conformational change in the presence of PE that led to random coil structure in its amidated N-terminal segment, 
H2N-I1–S10 and the absence of intra-peptide interactions between this segment and the amidated C-terminal segment, V16-
L20-NH2, of the peptide (Table 2) (Figs. 2B and 2C) [88, 110]. The N-terminal PE-binding sequence of the peptide showed 
significant homology to those of the bacterial AMPs, cinnamycin and duramycin, which suggested that the affinity of maximin 
H5 for the lipid may involve an ability to mimic structural properties of the PE-binding pocket formed by these prokaryotic 
peptides [110]. Consistent with this proposal, a CAMP with potent activity against the enveloped virus, human immune-
deficiency virus was produced by substituting arginine residues for the three aspartate residues of maximin H5 [117], thereby 
destabilising the PE binding conformation of the peptide [88, 110]. Taken in combination, these observations suggested that 
maximin H5 has high affinity for PE that induces immobilisation of the peptide on the surface of membranes, which include the 
lipid, thereby inhibiting the ability of maximin H5 to adopt the membrane interactive tilted α-helical structure necessary for its 
antimicrobial activity [88, 110]. 
 
3.4. The anticancer activity of maximin H5  
Currently, maximin H5 appears to be the only major focus of research into amphibian AAMPs with anticancer activity.  
XLAsp-P1 was shown to inhibit the growth of MCF-7 cells, which is a human breast adenocarcinoma cell line, but no further 
studies on mechanisms underpinning this activity of were conducted [33].  In contrast, several studies have shown that maximin 
H5 has activity against the T98G glioblastoma cell line and exhibits specificity for these cells over non-cancerous cells [29, 55]. 
These observations showed that, although PE is present the outer membrane leaflet of cancer cells [121-122], the affinity of the 
lipid for maximin H5 did not inhibit the action of the peptide against T98G glioblastoma cells, contrasting with the case of E. 
coli, described above (Fig. 2) [88, 110]. It was proposed that these effects were most likely related to the fact that the lipid 
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forms circa 80% of the E. coli inner membrane [123] but constitutes less than 30%  of the lipid in the outer membrane leaflet of 
T98G cells [124]. Indeed, on this premise, maximin H5 may show activity against other cancer cells, which generally exhibit 
lower levels of PE [125-126], as in the case of cells of the breast cancer cell line, MCF-7, which include around 15% of the 
lipid in their outer leaflet [127]. 
 
Characterisation of the anticancer action of maximin H5 showed that it adopted high levels of α-helical structure that facilitated 
membranolytic action against cancer cell membranes [55]. These studies also showed that this action was promoted by anionic 
lipid and required the presence of the peptide’s terminal amide moieties for optimal anticancer effect, supporting the view that 
maximin H5 effectively acts as a CAMP [54, 89].  It is well established that CAMPs interact with cancer and microbial 
membranes through generally similar mechanisms, targeting the negative surface charge carried by both these membrane types 
[128-129].  To investigate the interaction of maximin H5 with cancer cell membranes at the molecular level, here we present 
MD simulations of the peptide interacting with a bilayer composed of PC and PS in a 10:1 molar ratio. This lipid composition 
corresponds to that used to mimic cancer cell membranes in the experimental work of Dennison et al.,  [55] and consistent with 
this work, our MD simulations predicted that native maximin H5 would partition into these bilayers primarily through the 
formation of high levels of α-helical architecture (Fig.3A (i)). Similar to the antibacterial form of the native peptide [89] (Fig. 
2A), this α-helical architecture primarily resides in the segments, H2N-I1–S10 and V16-L20-NH2, of maximin H5 (Fig. 3A (i)). 
These segments of the peptide were predominantly associated with DMPS molecules in the membrane and facilitated 
penetration of the hydrophobic core of the bilayer, as indicated by the partial density profile of native maximin H5 (Fig. 3A 
(ii)). In particular, hydrophobic residues in the terminal segments of this peptide interacted with the acyl chains of DMPS whilst 
charged and polar residues in these segments associated with moieties in the head-group region of the lipid, such as phosphate 
groups. The overall lipid interactive conformation of native maximin H5 was stabilised by high levels of hydrogen bonding, 
which was predominantly between residues within these N-terminal and C-terminal segments and multiple components of the 
bilayer (Fig. 3A (i)). These observations are generally consistent with experimental work [55] and indicate that native maximin 
H5 has a strong preference for anionic lipid over zwitterionic lipid, providing a basis for the observed ability of PS to promote 
the membranolytic and anticancer action of the peptide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. MD simulations of maximin H5 interacting with cancer cell membranes. Figures 3A (i) and 3B (i) show side 
elevations of MD simulations for the interaction of maximin H5 and its deaminated isoform, respectively, with bilayers formed 
from DMPS / DMPC (10:1) and this lipid composition was taken to represent cancer cell membranes as previously described 
[130-131]. A detailed description of these lipid interactions is provided above but essentially, these simulations predicted that 
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both peptides partitioned into these bilayers via an N-terminal region comprising 10 residues and a shorter C-terminal segment. 
These MD simulations also generated partial density profiles and the graphics in each panel shows partial densities of the 
components in each peptide / lipid system (Figures 3A (ii) and 3B (ii): overall lipid density (solid black line), lipid head-groups 
(dotted line), lipid tails groups (dashed line) and peptide (solid line and indicated by arrows). A comparison of the partial 
density profiles for peptides, predicts that maximin H5 (Figure 3A (ii)) would penetrate the hydrophobic membrane core region 
of DMPS / DMPC (10:1) membranes more deeply than its deaminated isoform (Figure 3B (ii)). MD simulations were 
performed as previously described except that lipid bilayers were constructed from lipid mixtures of DMPS / DMPC in a molar 
ratio of 10:1 [88]. 
 
 
To investigate a requirement for the terminal amide groups in the anticancer activity, of maximin H5, our MD 
simulations were repeated using a C-terminally deaminated isoform of the peptide. Clearly, the loss of this C-terminal amide 
might be expected to reduce the membranolytic ability of the peptide through a decreased potential to interact with anionic lipid 
components of these membranes. However, our MD simulations predicted that deamination also would also lead to a loss of α-
helical structure in the C-terminal segment of native maximin H5 and a reduction in the level of hydrogen bonding between this 
segment and components of the bilayer (Fig.4B (i)). As indicated by the partial density profile of the deaminated peptide, these 
C-terminal effects appeared to contribute to a decrease in the depth of penetration shown by the peptide into the hydrophobic 
core of the bilayer (Fig. 3B (ii)) as compared to native maximin H5 (Fig. 3A (ii)). Graphical analysis shows that native 
maximin H5 is strongly amphiphilic in an α-helical conformation with a clear segregation of hydrophobic and hydrophilic 
residues (Fig. 4). In combination, these observations suggest that the C-terminal amide of the native peptide helps maintain the 
levels of amphiphilicity required for the optimal lysis of cancer cell membranes. Indeed, it is well established that the presence 
of C-terminal amide groups enhances the propensity of AMPs to form α-helical structure by making an additional hydrogen 
bond available for stabilisation of this structure [132-133]. Taken overall, our MD simulations strongly support experimental 
data suggesting that the C-terminal amide possessed by native maximin H5 plays a key role in optimising the ability of the 
peptide to kill cancer cells [55] and predict that it facilitates this ability through multiple functions related to the promotion of 
membrane targeting and interaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The amphiphilicity of maximin H5. Figure 4 shows α-helical maximin H5 displayed as a two-dimensional axial 
projection. This α-helical arrangement is strongly amphiphilic and shows a clear segregation of hydrophilic and hydrophobic 
amino acid residues. The wide apolar face of the α-helix is primarily formed by strongly hydrophobic residues, such as valine, 
leucine and isoleucine, whilst the narrow polar face is mainly formed from anionic, aspartic acid residues and glycine residues. 
The possession of a glycine-rich polar face is a feature shared by a number of tilted peptides [112] and it is believed that this 
segregation of glycine residues promotes a more favourable free energy of membrane insertion because the asymmetric 
distribution of the bulkier, hydrophobic residues along the other side of the α-helical axis is able to drive penetration of the 
membrane at a shallow angle [134]. 
 
 
CONCLUSIONS 
 Here, current research into amphibian AAMPs has been reviewed, which shows that the majority of these peptides have 
been identified in newts, frogs and toads (Table 2). A number of amphibians show the potential to produce the AAMPs, peptide 
B and enkelytin, which are cleaved from larger proteins, although this production has yet to be experimentally demonstrated 
(Table 3). The diversity of these amphibians taken with the fact that they are resident across wide geographical areas on a 
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number of continents would seem to reinforce the view that AAMPs are important components of innate immune systems [26-
29].  
 The net charge of the AAMPs reviewed here ranged from -1 to -8, and these peptides appear to use a variety of mechanisms 
to target and interact with microbes, such as the ability of maximin H5 to effectively function as a CAMP.  This would appear 
to be the first report of such behaviour for an amphibian peptide, although it has been described for AAMPs from plants [26, 
135]. In contrast, some AAMPs reviewed here are composed entirely of negatively charged residues, such as PYL, and appear 
to interact with microbial membranes by co-opting cationic metal ions to form salt bridges. However, other amphibian AAMPs 
entirely composed of anionic residues, such as XLAsp-P1, interact with membranes via mechanisms that are independent of 
cationic metal ions, and in these cases, the underpinning mechanisms are unclear. It seems likely that the membrane 
interactions of these peptides may involve association with positively charged components of the microbial membrane such as 
the ammonium moiety of PE and cationic lipids such as Lys-PG.  
 A number of the peptides reviewed here, including: he-1, thaulin-4, pleurain-C2, brevinin-1-AJ3, jingdongin-2 and PD-3-7, 
were either not tested for antimicrobial activity or found to be ineffective against the microbes assayed (Table 4). However, it 
seems possible that, in some cases, this apparent lack of antimicrobial action might simply represent the small ranges of 
bacteria and fungi that were generally used to assay this activity. For example, the amyloid-forming peptide, PD-3-7, was 
reported as possessing no antibacterial activity based on assays against only two organisms [52]. However, AMPs with 
amyloid-mediated antimicrobial mechanisms are increasingly being reported, and further studies on the ability of PD-3-7 to act 
in this capacity would seem to be merited [12, 60]. Interestingly, very recent studies have shown that human α-defensin 6 also 
lacks direct antibacterial activity but binds to surface proteins of these organisms, which triggers ordered self-assembly to form 
fibrils and amyloid nanonets that surround and entangle target bacteria [136]. Several of the AAMPs reviewed here were 
multifunctional with defensin-TK, CFBD-1, XLAsp-P2 and pleurain-C1 showing antifungal activity, whilst XLAsp-P1 and 
maximin H5 exhibited anticancer action. The remaining AAMPs were either ineffective against the fungi or cancer cells tested 
or were not assayed for activity against these target cells (Table 4). Several peptides showed other biological roles, such as 
insecticidal activity in the case of PD-3-7 and serving as a propeptide in the case of PYL (Table 4). Indeed, in the latter case, it 
appears that antimicrobial function is a secondary role for the peptide [31]: similar observations have been made for a number 
of non-amphibian AAMPs [26]. Maximin H5 appeared to be the only peptide reviewed here with neuropeptide function (Table 
4), although it has been predicted that a number of homologous AAMPs may share this property [56]. It would seem that this 
localisation of antimicrobial and neuropeptide capability within single peptides might be an important strategy for the 
promotion of a rapid unified neuroimmune response by the amphibian host. This strategy clearly differs fundamentally from 
that mediated by the processing of PENK where antimicrobial and neuropeptide functions reside separately in AAMPs and 
opioid peptides (Figure 1) [85-86]. Currently, the presence of this opioid hormone in B. maxima does not appear to have been 
investigated, although it has been identified in the brain of the closely related Oriental Fire-bellied Toad, Bombina orientalis 
(Table 3)[49]. In combination, these observations suggest that the brains of amphibians may have a number of strategies for 
providing a coordinated neuroimmune response to threats such as microbial challenge, stress, or other stimuli.  
 This review has shown that some progress has been made in elucidating the mechanisms underpinning the biological 
activities of amphibian AAMPs.  For example, XLAsp-P1 appeared to kill bacteria using a toroidal pore type mechanism, and 
the action of XLAsp-P2 shows hallmark characteristics of the SHM model of membrane interaction. This latter peptide also 
showed the ability to potentiate the action of conventional antibiotics against MDR pathogens, and the potential advantages of 
this form of combination therapy are increasingly being recognised and are viewed as a major, potential strategy for combating 
microbial pathogens with MDR [137-138]. For example, combination treatment can potentially reduce the required dosage of 
individual drugs, thereby diminishing side effects, as well as, not only eliminating resistant strains, but also delaying the 
emergence of drug resistance [139-140]. Indeed, it has been observed that combination therapy to potentiate failing antibiotics 
could be an interim solution to the global problem of MDR pathogens until sufficient numbers of novel antimicrobial molecules 
and strategies become available [141]. 
 Several AAMPs reviewed here, namely PD-3-7 and maximin H5, exhibited pH-dependent mechanisms of biological 
activity, which is relatively rare amongst amphibian AMPs [101]. In the case of PD-3-7, this activity appeared to involve 
epimerisation and pH-dependent amyloid formation, which led to the proposal that studies on amyloidogenesis by these 
epimers could help understand the pathogenesis of disease-related amyloid, such as AD [52-53]. It is well established that D-
enantiomers of residues are present in the Aβ peptides, and elevated levels of these residues have been described in amyloid 
plaques and the brain tissue of AD patients [142]. Based on the pH-dependent reversibility of amyloid formation by PD-3-7, it 
has also been proposed that studies on the peptide could aid the development of amyloid-based nanomaterials [52-53].  The 
ability of amyloid to reversibly self-assemble has been employed in the design of long-acting drugs where the sustained and 
controlled release of biologically active peptides occurs from the termini of fibrils [143]. Currently, the number of known 
amyloidogenic AAMPs is increasing [60], such as the recently reported Cn-AMP2 from the Coconut, Cocos nucifera [144].  In 
addition, functional amyloid nanostructures are being developed for use in a growing number of diverse areas, such as tissue 
repair / engineering, which is of high technological and medical importance [143, 145].  
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 In the case of maximin H5, there is strong evidence to suggest that the peptide kills S. aureus using a pH dependent 
membranolytic mode of action that encompasses tilted peptide formation. Interestingly, it can be seen from Figure 4 that the 
hydrophilic face of the tilted α-helix formed by maximin H5 is rich in glycine residues, a feature shared by a number of tilted 
peptides [112]. It is believed that this segregation of glycine residues promotes a more favourable free energy of membrane 
insertion because the asymmetric distribution of the bulkier, hydrophobic residues along the other side of the α-helical axis is 
able to drive penetration of the membrane at a shallow angle [134]. A number of amphibian AMPs with tilted structure 
incorporated into their lytic action have been previously reported [100, 106, 146] and together, these results have the potential 
to aid the design of novel AMPs with pH dependent biological activity, which is currently, a major area of research [101].  
Recent work has described such peptides for action against bacteria, fungi, biofilms and cancer cells, as well as for biotechnical 
applications involving the delivery of drugs and genes [101]. S. aureus has developed protection from the action of maximin 
H5 by modulating its membrane properties but the peptide has successfully overcome this defensive shield. It is notable that the 
membranolytic mode of action used by maximin H5 is enhanced by the low pH conditions that favour the growth of S. aureus 
[54]. This observation tempts the speculation that the secretion of the peptide by B. maxima [44], may have developed 
specifically to combat the organism, particularly in view of the fact that S. aureus appears to be the sole microbial target of the 
peptide [44, 117]. These observations would seem to provide a clear illustration of the co-evolutionary processes of mutual 
inhibition, evasion and adaptation strategies that characterise host-pathogen interactions [23], a scenario often referred to as the 
microbial ‘arms race’ [17-18, 147]. Moreover, given the low levels of haemolysis shown by maximin H5, it would seem that 
the peptide is worthy of further investigation as a potential template for development as an anti-staphylococcal agent [44, 54, 
89]. In contrast to S. aureus, E. coli exhibits resistance to the action of maximin H5, and this resistance appears to be based on 
the ability of the peptide to bind PE with high affinity. It has previously been suggested that some plant AAMPs and other 
AMPs with a similar affinity for PE may serve as lead compounds for tumour imaging [110, 148-149]. Interestingly, what 
would appear to be the first pH-dependent anionic, antimicrobial protein identified in amphibians was recently reported when 
phylogenetic analyses predicted that homologues of human psoriasin would be expressed in a number of amphibians [150]. It is 
well-established that human psoriasin exhibits Zn2+-dependent and pH-dependent activity in the antimicrobial defence of the 
skin [101], and a homologue of the protein, designated RtS100A7 (net charge -5) was detected in the skin secretions of the 
European Common Frog, Rana temporaria [150]. In contrast to human psoriasin, RtS100A7 was ineffective against E. coli at 
neutral pH, which appeared to result from an inability to form Zn2+ binding sites, a property that underpins activity of human 
psoriasin against the organism. However, similarly to human psoriasin, RtS100A7 showed membranolytic activity towards B. 
megaterium and B. subtilis at low pH, although this activity was weaker than that of human psoriasin. Based on these 
observations, it was proposed that RtS100A7 might function in the innate immunity of R. temporaria by synergising the 
activity of other AMPs in the skin of the amphibian [150]. 
 Maximin H5 and XLAsp-P1 were both found to exert anticancer activity, which would make these peptides the first 
amphibian AAMPs reported to possess this ability.  This reinforces the view that these creatures are becoming an increasingly 
important source of novel agents to combat cancer, a leading, global cause of death [151-152]. Indeed, AAMPs in general, are 
viewed as attractive propositions to stem the diminishing flow of effective, conventional anticancer compounds [99, 153-156], 
although currently, the majority of these peptides are primarily derived from plants [28-29]. The ability of maximin H5 and 
XLAsp-P1 to exert anticancer activity distinguishes these peptides from many AMPs, which do not exhibit this ability and the 
reason for this varying functionality is currently unclear [128-129, 156-157]. It is an open debate as to whether the possession 
of anticancer activity by AMPs has developed to give the host organism a survival advantage or it is just a matter of 
serendipity. However, it is interesting to note that there is a strong link between many microbial infections and cancers in 
humans [158-159], such as those due to human papillomaviruses where the insertion of viral DNA into human DNA can 
damage chromosomes and genes, resulting in cancers of the cervix, neck and head [160-163]. In this light, it can be envisaged 
that agents with the capacity to simultaneously attack cancers and their associated viral and bacterial infections would be 
therapeutically beneficial. Indeed, it would seem that the potential of maximin H5 to serve in this capacity could be enhanced 
by its plasticity as a template in the production of derivatives with multiple mechanisms of activity and differing specificities 
[54]. For example, maximin H5 possesses no antiviral properties itself [117], but nanomaterials based on the peptide were 
found to be active against phage λ [164-165], showing the potential to treat disease associated biofilms rendered recalcitrant to 
conventional antibiotics by phage infected bacteria [166]. 
 In summary, this review has shown that AAMPs are produced by creatures across Amphibia and that these peptides are 
primarily active against a variety of microbes and cancer cells. There has been some progress towards characterising these 
AAMPs and several have the potential for medical and biotechnological applications. Currently, the best characterised of these 
peptides is maximum H5, which primarily appears to provide a lead compound for the development of novel antibacterial, 
antiviral and anticancer compounds. However, in general, amphibian AAMPs appear to receive relatively little research 
attention and would seem to represent an untapped potential source of novel biologically active agents that merit far greater 
investigation.  
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